pre-IPO PHARMA

COMPANY OVERVIEW

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM and RenLiteTM mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development ability to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 potential druggable targets, known as Project Integrum, and has entered ongoing collaborations with dozens of partners worldwide to produce a variety of first-in-class and/or best-in-class antibody drugs. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany.


LOCATION


THERAPEUTIC AREAS


WEBSITE

None


CAREER WEBSITE

None


SOCIAL MEDIA


INVESTORS


PRESS RELEASES


May 24, 2022

Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting USA - English España - español France - Français Deutschland - Deutsch


Apr 29, 2022

Biocytogen Enters into Antibody Agreement with Merck KGaA, Darmstadt, Germany


Apr 25, 2022

Biocytogen Signs RenMab™/RenLite™ Licensing Agreement with BeiGene USA - English España - español Deutschland - Deutsch France - Français


Apr 18, 2022

Biocytogen Enters Agreement With CtM Bio to Co-develop TCR-Mimic Antibody-Based Multi-Specific T cell Engagers


Apr 7, 2022

Eucure Biopharma, filiale de Biocytogen, termine le dosage du premier patient de l'essai clinique de phase I de la trithérapie YH003 (anticorps anti-CD40) France - Français USA - English España - español Deutschland - Deutsch


For More Press Releases


Google Analytics Alternative